Nov 4, 7:01 AM ET
Insulet reported third-quarter 2026 revenue of $842.0 million, up 19.2%, and net income of $141.1 million, or $2.03 per diluted share, compared with $87.6 million, or $1.24 per diluted share, a year earlier. The company raised its low-end total revenue guidance for 2026 to 21%-22% from 20%-22% and expects adjusted operating margin to expand about 150 basis points, up from about 100 basis points, and its board approved a $1 billion share repurchase program.
- Q3 revenue of $842.0 million, up 19.2% (19.6% in constant currency), above the high end of the 17.5%-19.5% constant-currency guidance range
- Net income of $141.1 million, or $2.03 per diluted share, versus $87.6 million, or $1.24 per diluted share; adjusted EPS was $1.99
- FY 2026 total revenue guidance (constant currency) of 21%-22%, up from 20%-22%; adjusted operating margin expansion of about 150 bps versus about 100 bps prior
- Board authorized repurchases of up to $1 billion through December 31, 2028, with about $400 million planned for Q4 2026 using existing cash
Read the filing on SEC.gov ↗
Sep 21, 5:02 PM ET
On September 21, 2026, Insulet entered into a Ninth Amendment to its Credit Agreement with Morgan Stanley Senior Funding as administrative agent. The $475 million of existing term loans were replaced with new term loans at a margin 0.25% lower, and revolving commitments rose by $250 million to $750 million, which were undrawn at closing. For shareholders, the filing points to lower borrowing costs and more available credit, though it does not state a dollar effect on earnings.
- New term loans of $475 million replaced existing term loans of equal amount, issued at par.
- Term SOFR loan margin on new term loans is 1.75%, 0.25% lower than the existing margin, with a 0.00% SOFR floor.
- Revolving credit commitments increased by $250 million to $750 million, undrawn at closing; term SOFR margin range cut to 1.25% to 1.75%.
Read the filing on SEC.gov ↗
Sep 16, 4:03 PM ET
Insulet's Talent and Compensation Committee approved a nonqualified deferred compensation plan on September 14, 2026, effective January 1, 2027, letting selected management and highly compensated employees defer up to 60% of cash pay. The plan also allows discretionary company contributions, with vesting tied to service and full vesting on a change in control.
- Plan approved September 14, 2026 and effective January 1, 2027
- Participants may defer up to 60% of base salary, annual bonus and other approved cash compensation
- Company matching or discretionary contributions generally vest on a two-year cliff schedule and fully vest on a change in control
- Committee can terminate or amend the plan, but cannot reduce accrued participant benefits
Read the filing on SEC.gov ↗
Sep 10, 4:02 PM ET
Insulet directors Timothy J. Scannell and Michael R. Minogue are stepping down from the board, effective September 3 and September 15, 2026, respectively. Scannell cited health reasons, and Minogue is leaving to focus on his candidacy for Governor of Massachusetts; the filing says neither departure stems from a disagreement with the company.
- Timothy J. Scannell, who served 12 years on the board including 7 years as Chairman, steps down effective September 3, 2026, citing health reasons
- Michael R. Minogue, who served 9 years, notified the company on September 8, 2026 and steps down effective September 15, 2026 to pursue a run for Governor of Massachusetts
- The filing states neither director resigned due to a disagreement with the company on operations, policies or practices
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.